Business
Pathos AI brings its agentic drug-development platform to Alzheimer's with Bristol Myers Squibb and Tempus, as BMS leads a $237 million round
Pathos AI will license a large neurology dataset from Tempus and give Bristol Myers Squibb access to its Foundry platform, including three years of neuroscience exclusivity, while closing a BMS-led Series E that values t…